Concerns Over GLP-1 Obesity Drugs and FDA’s Green List

During an event addressing the risks posed by China, Patsy Reitman from RX Border Defense spoke with Matthew Boyle from Breitbart News. She expressed her worry that the U.S. Food and Drug Administration (FDA) is allowing Chinese firms to dominate the GLP-1 obesity drug market, which could jeopardize Americans’ safety.

Reitman highlighted that many Chinese manufacturers of GLP-1 drugs are on the FDA’s “green list,” indicating they are deemed safe for entry into the U.S. She argued that this could create a situation where drugs with potentially lax safety measures flood the market, leaving consumers in the dark about what they are actually taking.

“Currently, over half of the companies not being detained for safety issues are based in China,” Reitman noted. RX Border Defense, a non-profit group focused on fighting counterfeit medicine, has raised alarms about the uneven standards applied to U.S. consumers and companies compared to those for foreign entities.

She pointed out an alarming example involving a Chinese company, Sinopep. According to an FDA letter, inspectors found serious sanitation issues, including the presence of insects and unwanted bacteria. Despite these findings, the company remains on the approval list for compounded GLP-1 drugs, which are versions not sanctioned by the FDA.

Labeling obesity drugs as “China’s test balloon,” Reitman shared that a simple Google search for these medications yielded numerous advertisements, without much transparency about their origins or ingredients. “As someone who’s quite informed in this area, I found it frustrating not to get clear details about what I was looking at. Even the ads mentioned FDA approval for the drugs, but the intricacies of those approvals could lead to serious risks,” she explained.

Boyle mentioned over 1,500 adverse effects associated with GLP-1 drugs reported by the FDA, though Reitman suggested the number could actually be much higher. She recounted a particularly troubling case of a woman in Kentucky who suffered kidney failure after just one month on the drug. “Imagine if a bad batch affected a thousand users—who would be accountable for that?” Reitman asked.

Raul López, also from RX Border Defense, questioned the rationale behind allowing companies from countries with adverse philosophies to appear on the FDA’s green list. “It’s unsettling that we have a green light for communist states—shouldn’t that raise alarms?” he remarked.

Chad Wolf, a former Acting Secretary of Homeland Security, acknowledged the idea of a classification system for safe and unsafe materials but raised doubts about the efficiency of the current Green List. “We face a real risk with Americans being sickened or worse because they’re oblivious to what they’re consuming,” he cautioned, emphasizing that this might quickly escalate into a national security concern.